Last reviewed · How we verify
SY-004
At a glance
| Generic name | SY-004 |
|---|---|
| Sponsor | Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus (PHASE2)
- A Drug Interaction Study of SY-004 Capsules in Healthy Subjects (PHASE1)
- A Food-drug Interaction Study of SY-004 in Healthy Subjects (PHASE1)
- Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus (PHASE1)
- The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SY-004 CI brief — competitive landscape report
- SY-004 updates RSS · CI watch RSS
- Suzhou Yabao Pharmaceutical R&D Co., Ltd. portfolio CI